{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:41:49Z","timestamp":1791571309500,"version":"4.3.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic ovarian syndrome (PCOS) is a widespread syndrome that poses unique challenges and constraints to the field of assisted reproductive technology. This condition is the most common cause of anovulation among infertile couples. Debate exists over the best therapeutic course of action when patients with PCOS proceed to IVF. In this review, we evaluate the best-performing and safest methods of IVF preparation, ovarian stimulation, trigger method for maturation of stimulated egg growth, and planning for embryo transfer. Pre-IVF considerations include being aware of individual AMH and vitamin D levels as well as BMI prior to selecting an ovarian stimulation protocol. Numerous supplements such as myo-inositol complement the benefits of lifestyle change and may enhance IVF performance including oocyte yield and pregnancy rate. Concerning stimulation protocols, antagonist cycles with the judicious use of GnRH agonist trigger, pre-treatment with metformin and vitamin D repletion may help mitigate the accompanied risk of ovarian hyperstimulation syndrome (OHSS). Following ovarian stimulation, PCOS patients typically undergo programmed frozen embryo transfer (FET) cycles which are more conducive for women with irregular cycles, but likely carry a higher risk of hypertensive disorders of pregnancy. However, newer stimulated FET protocols using Letrozole may offer improved outcomes. Overall, patients with PCOS require careful individual tailoring of their IVF cycle to achieve optimal results.<\/jats:p>","DOI":"10.1186\/s12958-023-01120-7","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T04:02:11Z","timestamp":1690862531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes"],"prefix":"10.1186","volume":"21","author":[{"given":"Alexander M.","family":"Kotlyar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Seifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"6","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/humupd\/dmw025","volume":"22","author":"AH Balen","year":"2016","unstructured":"Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687\u2013708.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2010","unstructured":"March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544\u201351.","journal-title":"Hum Reprod"},{"issue":"6","key":"1120_CR3","first-page":"65","volume":"195","author":"HJ Teede","year":"2011","unstructured":"Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011;195(6):65\u2013112.","journal-title":"Med J Aust"},{"issue":"1","key":"1120_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/jc.2006-1582","volume":"92","author":"L Pellatt","year":"2007","unstructured":"Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al. Granulosa cell production of anti-M\u00fcllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/REP-09-0415","volume":"139","author":"L Pellatt","year":"2010","unstructured":"Pellatt L, Rice S, Mason HD. Anti-M\u00fcllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010;139(5):825\u201333.","journal-title":"Reproduction"},{"issue":"3","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/humrep\/des460","volume":"28","author":"A Pierre","year":"2013","unstructured":"Pierre A, Peign\u00e9 M, Grynberg M, Arouche N, Taieb J, Hesters L, et al. Loss of LH-induced down-regulation of anti-M\u00fcllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod. 2013;28(3):762\u20139.","journal-title":"Hum Reprod"},{"issue":"7","key":"1120_CR7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/humrep\/dep074","volume":"24","author":"SM Carlsen","year":"2009","unstructured":"Carlsen SM, Vanky E, Fleming R. Anti-M\u00fcllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod. 2009;24(7):1732\u20138.","journal-title":"Hum Reprod"},{"issue":"1","key":"1120_CR8","doi-asserted-by":"publisher","first-page":"59e1","DOI":"10.1016\/j.ajog.2014.02.026","volume":"211","author":"R Tal","year":"2014","unstructured":"Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antim\u00fcllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(1):59e1\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"1120_CR9","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/humrep\/deab181","volume":"36","author":"S Palomba","year":"2021","unstructured":"Palomba S. Is fertility reduced in ovulatory women with polycystic ovary syndrome? An opinion paper. Hum Reprod. 2021;36(9):2421\u20138.","journal-title":"Hum Reprod"},{"issue":"3","key":"1120_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/humupd\/dmaa051","volume":"27","author":"S Palomba","year":"2021","unstructured":"Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27(3):584\u2013618.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"1120_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tem.2016.11.008","volume":"28","author":"S Palomba","year":"2017","unstructured":"Palomba S, Daolio J, La Sala GB. Oocyte competence in women with polycystic ovary syndrome. Trends Endocrinol Metab. 2017;28(3):186\u201398.","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"1120_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/humupd\/dmv029","volume":"21","author":"S Palomba","year":"2015","unstructured":"Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575\u201392.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"1120_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1313517","volume":"371","author":"RS Legro","year":"2014","unstructured":"Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119\u201329.","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"1120_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1242\/dmm.001180","volume":"2","author":"PL Huang","year":"2009","unstructured":"Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5\u20136):231\u20137.","journal-title":"Dis Model Mech"},{"issue":"1","key":"1120_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.12891\/ceog16312014","volume":"41","author":"Y Zhen","year":"2014","unstructured":"Zhen Y, Yang P, Dong R, Wu Y, Sang Y, Du X, et al. Effect of HbA1C detection on the diagnostic screening for glucose metabolic disorders in polycystic ovary syndrome. Clin Exp Obstet Gynecol. 2014;41(1):58\u201361.","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"1","key":"1120_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.22.1.141","volume":"22","author":"DA Ehrmann","year":"1999","unstructured":"Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141\u20136.","journal-title":"Diabetes Care"},{"issue":"9","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602\u201318.","journal-title":"Hum Reprod"},{"issue":"9","key":"1120_CR18","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-020-01209-5","volume":"43","author":"L Gao","year":"2020","unstructured":"Gao L, Li M, Wang Y, Zeng Z, Xie Y, Liu G, et al. Overweight and high serum total cholesterol were risk factors for the outcome of IVF\/ICSI cycles in PCOS patients and a PCOS-specific predictive model of live birth rate was established. J Endocrinol Invest. 2020;43(9):1221\u20138.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1120_CR19","doi-asserted-by":"publisher","first-page":"163e1","DOI":"10.1016\/j.ajog.2014.03.035","volume":"211","author":"AP Bailey","year":"2014","unstructured":"Bailey AP, Hawkins LK, Missmer SA, Correia KF, Yanushpolsky EH. Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. Am J Obstet Gynecol. 2014;211(2):163e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1120_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/humupd\/dmz013","volume":"25","author":"GP Mena","year":"2019","unstructured":"Mena GP, Mielke GI, Brown WJ. The effect of physical activity on reproductive health outcomes in young women: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(5):541\u201363.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"1120_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/humrep\/dew325","volume":"32","author":"D Wei","year":"2017","unstructured":"Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2017;32(2):354\u201361.","journal-title":"Hum Reprod"},{"issue":"8","key":"1120_CR22","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/jog.14858","volume":"47","author":"E Hatirnaz","year":"2021","unstructured":"Hatirnaz E, Hatirnaz S, Kanat-Pektas M, Dokuzeylul Gungor N, Erol O, Kalyoncu S, et al. The impact of timing for estrogen supplementation in polycystic ovary syndrome patients undergoing primed in vitro maturation. J Obstet Gynaecol Res. 2021;47(8):2684\u201391.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"1120_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rbmo.2016.04.007","volume":"33","author":"D Garg","year":"2016","unstructured":"Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016;33(1):15\u201328.","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"1120_CR24","first-page":"347","volume":"11","author":"S Gerli","year":"2007","unstructured":"Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347\u201354.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"1120_CR25","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.fertnstert.2008.01.088","volume":"91","author":"E Papaleo","year":"2009","unstructured":"Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009;91(5):1750\u20134.","journal-title":"Fertil Steril"},{"issue":"4","key":"1120_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00404-018-4861-y","volume":"298","author":"AS Lagan\u00e0","year":"2018","unstructured":"Lagan\u00e0 AS, Vitagliano A, Noventa M, Ambrosini G, D\u2019Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298(4):675\u201384.","journal-title":"Arch Gynecol Obstet"},{"issue":"49","key":"1120_CR27","doi-asserted-by":"publisher","first-page":"e8842","DOI":"10.1097\/MD.0000000000008842","volume":"96","author":"X Zheng","year":"2017","unstructured":"Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Med (Baltim). 2017;96(49):e8842.","journal-title":"Med (Baltim)"},{"key":"1120_CR28","doi-asserted-by":"crossref","unstructured":"Russo M, Forte G, Montanino Oliva M, Lagan\u00e0 AS, Unfer V. Melatonin and Myo-Inositol: supporting Reproduction from the oocyte to Birth. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22168433"},{"issue":"6","key":"1120_CR29","first-page":"555","volume":"14","author":"P Rizzo","year":"2010","unstructured":"Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010;14(6):555\u201361.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1120_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/NSS.S127475","volume":"10","author":"RC Fernandez","year":"2018","unstructured":"Fernandez RC, Moore VM, Van Ryswyk EM, Varcoe TJ, Rodgers RJ, March WA, et al. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Nat Sci Sleep. 2018;10:45\u201364.","journal-title":"Nat Sci Sleep"},{"issue":"1","key":"1120_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/09513590.2015.1101444","volume":"32","author":"A Pacchiarotti","year":"2016","unstructured":"Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2016;32(1):69\u201373.","journal-title":"Gynecol Endocrinol"},{"key":"1120_CR32","doi-asserted-by":"crossref","unstructured":"Regidor PA, Schindler AE, Lesoine B, Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig. 2018;34(2).","DOI":"10.1515\/hmbci-2017-0067"},{"key":"1120_CR33","doi-asserted-by":"publisher","first-page":"6273298","DOI":"10.1155\/2016\/6273298","volume":"2016","author":"A Wdowiak","year":"2016","unstructured":"Wdowiak A. Myoinositol improves embryo development in PCOS Patients undergoing ICSI. Int J Endocrinol. 2016;2016:6273298.","journal-title":"Int J Endocrinol"},{"issue":"2","key":"1120_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/09513590.2014.964640","volume":"31","author":"Z Kamenov","year":"2015","unstructured":"Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015;31(2):131\u20135.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1120_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13048-018-0411-2","volume":"11","author":"M Montanino Oliva","year":"2018","unstructured":"Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018;11(1):38.","journal-title":"J Ovarian Res"},{"issue":"8","key":"1120_CR36","first-page":"3316","volume":"25","author":"I Hernandez Marin","year":"2021","unstructured":"Hernandez Marin I, Picconi O, Lagan\u00e0 AS, Costabile L, Unfer V. A multicenter clinical study with myo-inositol and alpha-lactalbumin in mexican and italian PCOS patients. Eur Rev Med Pharmacol Sci. 2021;25(8):3316\u201324.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1120_CR37","doi-asserted-by":"publisher","first-page":"809419","DOI":"10.3389\/fphys.2021.809419","volume":"12","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Pan Y, Li P, Wang Z, Wang Z, Shi Y. Ovarian sensitivity decreased significantly in patients with insulin resistance undergoing in vitro fertilization and embryo transfer. Front Physiol. 2021;12:809419.","journal-title":"Front Physiol"},{"issue":"6","key":"1120_CR38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/humrep\/del025","volume":"21","author":"T Tang","year":"2006","unstructured":"Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006;21(6):1416\u201325.","journal-title":"Hum Reprod"},{"issue":"10","key":"1120_CR39","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1177\/1933719118765985","volume":"26","author":"OS Abdalmageed","year":"2019","unstructured":"Abdalmageed OS, Farghaly TA, Abdelaleem AA, Abdelmagied AE, Ali MK, Abbas AM. Impact of metformin on IVF outcomes in overweight and obese women with polycystic ovary syndrome: a Randomized double-blind controlled trial. Reprod Sci. 2019;26(10):1336\u201342.","journal-title":"Reprod Sci"},{"issue":"12","key":"1120_CR40","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1093\/humrep\/dew268","volume":"31","author":"SL Jacob","year":"2016","unstructured":"Jacob SL, Brewer C, Tang T, Picton HM, Barth JH, Balen AH. A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Hum Reprod. 2016;31(12):2756\u201364.","journal-title":"Hum Reprod"},{"issue":"12","key":"1120_CR41","first-page":"Cd006105","volume":"12","author":"LO Tso","year":"2020","unstructured":"Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12(12):Cd006105.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1120_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1\u201311.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1120_CR43","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00394-018-1760-8","volume":"58","author":"C Trummer","year":"2019","unstructured":"Trummer C, Schwetz V, Kollmann M, W\u00f6lfler M, M\u00fcnzker J, Pieber TR, et al. Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial. Eur J Nutr. 2019;58(5):2019\u201328.","journal-title":"Eur J Nutr"},{"issue":"6","key":"1120_CR44","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.fertnstert.2014.02.021","volume":"101","author":"N Raja-Khan","year":"2014","unstructured":"Raja-Khan N, Shah J, Stetter CM, Lott ME, Kunselman AR, Dodson WC, et al. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril. 2014;101(6):1740\u20136.","journal-title":"Fertil Steril"},{"issue":"3","key":"1120_CR45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3945\/ajcn.115.126359","volume":"104","author":"L Abadia","year":"2016","unstructured":"Abadia L, Gaskins AJ, Chiu YH, Williams PL, Keller M, Wright DL, et al. Serum 25-hydroxyvitamin D concentrations and treatment outcomes of women undergoing assisted reproduction. Am J Clin Nutr. 2016;104(3):729\u201335.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"1120_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejogrb.2011.07.006","volume":"159","author":"A Aleyasin","year":"2011","unstructured":"Aleyasin A, Hosseini MA, Mahdavi A, Safdarian L, Fallahi P, Mohajeri MR, et al. Predictive value of the level of vitamin D in follicular fluid on the outcome of assisted reproductive technology. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):132\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"1120_CR47","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/humrep\/dew107","volume":"31","author":"A van de Vijver","year":"2016","unstructured":"van de Vijver A, Drakopoulos P, Van Landuyt L, Vaiarelli A, Blockeel C, Santos-Ribeiro S, et al. Vitamin D deficiency and pregnancy rates following frozen-thawed embryo transfer: a prospective cohort study. Hum Reprod. 2016;31(8):1749\u201354.","journal-title":"Hum Reprod"},{"issue":"1","key":"1120_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12978-019-0769-7","volume":"16","author":"J Chu","year":"2019","unstructured":"Chu J, Gallos I, Tobias A, Robinson L, Kirkman-Brown J, Dhillon-Smith R, et al. Vitamin D and assisted reproductive treatment outcome: a prospective cohort study. Reprod Health. 2019;16(1):106.","journal-title":"Reprod Health"},{"key":"1120_CR49","doi-asserted-by":"crossref","unstructured":"Irani M, Seifer DB, Grazi RV, Irani S, Rosenwaks Z, Tal R. Vitamin D decreases serum VEGF correlating with clinical improvement in vitamin D-Deficient women with PCOS: a randomized placebo-controlled trial. Nutrients. 2017;9(4).","DOI":"10.3390\/nu9040334"},{"issue":"11","key":"1120_CR50","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1210\/jc.2015-2580","volume":"100","author":"M Irani","year":"2015","unstructured":"Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, et al. Vitamin D supplementation decreases TGF-\u03b21 bioavailability in PCOS: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2015;100(11):4307\u201314.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1120_CR51","doi-asserted-by":"publisher","first-page":"E886","DOI":"10.1210\/jc.2013-4374","volume":"99","author":"M Irani","year":"2014","unstructured":"Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab. 2014;99(5):E886\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1120_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/humrep\/dep436","volume":"25","author":"TG Lainas","year":"2010","unstructured":"Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod. 2010;25(3):683\u20139.","journal-title":"Hum Reprod"},{"issue":"6","key":"1120_CR53","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/humrep\/dew051","volume":"31","author":"M Toftager","year":"2016","unstructured":"Toftager M, Bogstad J, Bryndorf T, L\u00f8ssl K, Rosk\u00e6r J, Holland T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles. Hum Reprod. 2016;31(6):1253\u201364.","journal-title":"Hum Reprod"},{"issue":"1","key":"1120_CR54","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1038\/s41598-022-08400-z","volume":"12","author":"S Kadoura","year":"2022","unstructured":"Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF\/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Sci Rep. 2022;12(1):4456.","journal-title":"Sci Rep"},{"issue":"3","key":"1120_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11596-019-2055-x","volume":"39","author":"ZN Xiao","year":"2019","unstructured":"Xiao ZN, Peng JL, Yang J, Xu WM. Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: comparison of clinical outcomes and ovarian response. Curr Med Sci. 2019;39(3):431\u20136.","journal-title":"Curr Med Sci"},{"issue":"1","key":"1120_CR56","doi-asserted-by":"publisher","first-page":"22732","DOI":"10.1038\/s41598-021-02227-w","volume":"11","author":"TC Huang","year":"2021","unstructured":"Huang TC, Huang MZ, Seow KM, Yang IJ, Pan SP, Chen MJ, et al. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol. Sci Rep. 2021;11(1):22732.","journal-title":"Sci Rep"},{"issue":"2","key":"1120_CR57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10815-019-01662-z","volume":"37","author":"T Abe","year":"2020","unstructured":"Abe T, Yabuuchi A, Ezoe K, Skaletsky H, Fukuda J, Ueno S, et al. Success rates in minimal stimulation cycle IVF with clomiphene citrate only. J Assist Reprod Genet. 2020;37(2):297\u2013304.","journal-title":"J Assist Reprod Genet"},{"issue":"6","key":"1120_CR58","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1055\/s-0042-100206","volume":"76","author":"D Fischer","year":"2016","unstructured":"Fischer D, Reisenb\u00fcchler C, R\u00f6sner S, Haussmann J, Wimberger P, Goeckenjan M, Avoiding OHSS. Controlled ovarian low-dose stimulation in women with PCOS. Geburtshilfe Frauenheilkd. 2016;76(6):718\u201326.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"1120_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/humupd\/dmaa035","volume":"27","author":"AK Datta","year":"2021","unstructured":"Datta AK, Maheshwari A, Felix N, Campbell S, Nargund G. Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(2):229\u201353.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"1120_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","volume":"89","author":"L Engmann","year":"2008","unstructured":"Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84\u201391.","journal-title":"Fertil Steril"},{"key":"1120_CR61","doi-asserted-by":"crossref","unstructured":"Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014(10):Cd008046.","DOI":"10.1002\/14651858.CD008046.pub4"},{"issue":"3","key":"1120_CR62","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.fertnstert.2008.12.042","volume":"93","author":"P Humaidan","year":"2010","unstructured":"Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010;93(3):847\u201354.","journal-title":"Fertil Steril"},{"issue":"12","key":"1120_CR63","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/humrep\/der333","volume":"26","author":"B Radesic","year":"2011","unstructured":"Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod. 2011;26(12):3437\u201342.","journal-title":"Hum Reprod"},{"issue":"3","key":"1120_CR64","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.fertnstert.2010.09.023","volume":"95","author":"EG Papanikolaou","year":"2011","unstructured":"Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011;95(3):1174\u20137.","journal-title":"Fertil Steril"},{"issue":"11","key":"1120_CR65","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1210\/en.2006-0657","volume":"147","author":"R Gomez","year":"2006","unstructured":"Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147(11):5400\u201311.","journal-title":"Endocrinology"},{"issue":"8","key":"1120_CR66","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1210\/jc.2011-0075","volume":"96","author":"R G\u00f3mez","year":"2011","unstructured":"G\u00f3mez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, Zimmermann RC, et al. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab. 2011;96(8):2484\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1120_CR67","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1210\/jc.2007-0409","volume":"92","author":"C Alvarez","year":"2007","unstructured":"Alvarez C, Mart\u00ed-Bonmat\u00ed L, Novella-Maestre E, Sanz R, G\u00f3mez R, Fern\u00e1ndez-S\u00e1nchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92(8):2931\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1120_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5468\/ogs.21067","volume":"64","author":"ES Rubenfeld","year":"2021","unstructured":"Rubenfeld ES, Dahan MH. Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome? Obstet Gynecol Sci. 2021;64(4):345\u201352.","journal-title":"Obstet Gynecol Sci"},{"issue":"3","key":"1120_CR69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.rbmo.2019.04.014","volume":"39","author":"G Shrem","year":"2019","unstructured":"Shrem G, Steiner N, Balayla J, Volodarsky-Perel A, Tannus S, Son WY, et al. Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2019;39(3):433\u20138.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"1120_CR70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","volume":"29","author":"ES Tehraninejad","year":"2012","unstructured":"Tehraninejad ES, Hafezi M, Arabipoor A, Aziminekoo E, Chehrazi M, Bahmanabadi A. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet. 2012;29(3):259\u201364.","journal-title":"J Assist Reprod Genet"},{"issue":"6","key":"1120_CR71","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1513873","volume":"375","author":"ZJ Chen","year":"2016","unstructured":"Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"1120_CR72","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1093\/humrep\/deaa226","volume":"35","author":"S Santos-Ribeiro","year":"2020","unstructured":"Santos-Ribeiro S, Mackens S, Popovic-Todorovic B, Racca A, Polyzos NP, Van Landuyt L, et al. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF\/ICSI for high responders: a randomized controlled trial. Hum Reprod. 2020;35(12):2808\u201318.","journal-title":"Hum Reprod"},{"issue":"6","key":"1120_CR73","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/aogs.14058","volume":"100","author":"Y Man","year":"2021","unstructured":"Man Y, Bian Y, Zhao S, Zhao R, Xu X, Wei D, et al. The effect of different endometrial preparations on women with polycystic ovary syndrome undergoing initial frozen embryo transfer: a historical cohort analysis. Acta Obstet Gynecol Scand. 2021;100(6):1116\u201323.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6","key":"1120_CR74","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/uog.15898","volume":"48","author":"M Kollmann","year":"2016","unstructured":"Kollmann M, Martins WP, Lima ML, Craciunas L, Nastri CO, Richardson A, et al. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2016;48(6):709\u201318.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"1120_CR75","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/09513590.2020.1867976","volume":"37","author":"MF Zeng","year":"2021","unstructured":"Zeng MF, Zhou X, Duan JL. Stimulated cycle versus artificial cycle for frozen embryo transfer in patients with polycystic ovary syndrome: a Meta-analysis. Gynecol Endocrinol. 2021;37(4):294\u20139.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1120_CR76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ajog.2021.01.024","volume":"225","author":"J Zhang","year":"2021","unstructured":"Zhang J, Wei M, Bian X, Wu L, Zhang S, Mao X, et al. Letrozole-induced frozen embryo transfer cycles are associated with a lower risk of hypertensive disorders of pregnancy among women with polycystic ovary syndrome. Am J Obstet Gynecol. 2021;225(1):59.e1-.e9.","journal-title":"Am J Obstet Gynecol"},{"key":"1120_CR77","doi-asserted-by":"crossref","unstructured":"Jiang NX, Li XL. The Disorders of Endometrial Receptivity in PCOS and its mechanisms. Reprod Sci. 2021.","DOI":"10.1007\/s43032-021-00629-9"},{"issue":"10","key":"1120_CR78","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1093\/humrep\/deu154","volume":"29","author":"V De Fr\u00e8ne","year":"2014","unstructured":"De Fr\u00e8ne V, Vansteelandt S, T\u2019Sjoen G, Gerris J, Somers S, Vercruysse L, et al. A retrospective study of the pregnancy, delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome. Hum Reprod. 2014;29(10):2333\u20138.","journal-title":"Hum Reprod"},{"issue":"10","key":"1120_CR79","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/humrep\/dev187","volume":"30","author":"M Kollmann","year":"2015","unstructured":"Kollmann M, Klaritsch P, Martins WP, Guenther F, Schneider V, Herzog SA, et al. Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. Hum Reprod. 2015;30(10):2396\u2013403.","journal-title":"Hum Reprod"},{"issue":"6","key":"1120_CR80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/humupd\/dml036","volume":"12","author":"CM Boomsma","year":"2006","unstructured":"Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673\u201383.","journal-title":"Hum Reprod Update"},{"issue":"4","key":"1120_CR81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/14767058.2014.921673","volume":"28","author":"HL Wan","year":"2015","unstructured":"Wan HL, Hui PW, Li HW, Ng EH. Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing in vitro fertilization: a retrospective cohort analysis. J Matern Fetal Neonatal Med. 2015;28(4):475\u20138.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"1120_CR82","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12884-019-2611-1","volume":"19","author":"J Lin","year":"2019","unstructured":"Lin J, Huang J, Wang N, Kuang Y, Cai R. Effects of pre-pregnancy body mass index on pregnancy and perinatal outcomes in women with PCOS undergoing frozen embryo transfer. BMC Pregnancy Childbirth. 2019;19(1):487.","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01120-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T05:02:48Z","timestamp":1690866168000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01120-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01120-7","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AMK declares no competing interests. DBS declares royalties from a license agreement between Rutgers Medical School\/MGH and Beckman Coulter for Anti-M\u00fcllerian hormone as a measure of ovarian reserve and Medical Advisory Board for Womens Integrated Network Honorarium outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}